Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
3472 Results for "
Prothrombin complex concentrate
" in MedChemExpress (MCE) Product Catalog:
Products (3472)
3472 Results for "Prothrombin complex concentrate" in MCE Product Catalog:
Cat. No.: HY-124940
CAS No.: 446877-42-5
Target:
Research Areas:
CPU-228 is a complex class III antiarrhythmic agent. CPU-228 concentration-dependently blocks the activities of the rapid component 50 of the delayed rectifier potassium channel (IKr) and the L-type calcium channel (ICa,L), with an IC50 value of 0.909 μM for ICa,L current. CPU-228 produces negative inotropic effects and induces mild, non-frequency-dependent prolongation of the effective refractory period (ERP) in isolated left atria. CPU-228 reduces the incidence of torsades de pointes (TDP) in anesthetized rabbits and inhibits ischemia/reperfusion-induced arrhythmias in rats. CPU-228 can be used in studies related to torsades de pointes .
Cat. No.: HY-134813A
MRTX1133 formic is a noncovalent, potent, and selective KRAS G12D inhibitor. MRTX1133 formic optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated KD against KRAS G12D of 0.2 pM. MRTX1133 formic prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRASG12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 formic shows efficacy in tumor models harboring KRAS G12D mutations .
Cat. No.: HY-13803R
CAS No.: 1403254-99-8
Synonyms: EPZ-6438 (Standard); E-7438 (Standard)
Research Areas:
Tazemetostat (Standard) is the analytical standard of Tazemetostat. This product is intended for research and analytical applications. Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM. Tazemetostat inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC50 of 4 nM. Tazemetostat also inhibits EZH1 with an IC50 of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells .
Target:
Cat. No.: HY-162813
Target:
Research Areas:
PROTAC SMARCA2/4 degrader-25 is a selective SMARCA2/SMARCA4 PROTAC degrader with selective anti-tumor activity. PROTAC SMARCA2/4 degrader-25 is activated by endogenous GSH, forms a ternary complex with SMARCA2 or SMARCA4 and VHL E3 ubiquitin ligase, and mediates degradation via the proteasome pathway. PROTAC SMARCA2/4 degrader-25 induces DNA damage and apoptosis, and inhibits cancer cell proliferation. PROTAC SMARCA2/4 degrader-25 is applicable to lung cancer-related research .
Cat. No.: HY-174996
CAS No.: 3031840-36-2
Target:
Research Areas:
NEP162 is a BRD4 PROTAC degrader based on the E3 ubiquitin ligase GID4, with DC50 values of 1.2 μM and 1.6 μM in SW480 and U2OS cells, respectively, and a Kd value of 0.13 µM for GID4. NEP162 bridges the E3 ligase GID4 and BRD4 to form a ternary complex, promotes polyubiquitination and subsequent degradation of BRD4 via the ubiquitin-proteasome system, reduces the proliferation capacity of tumor cells and induces apoptosis. NEP162 can be used for research on cancers such as osteosarcoma, colorectal cancer and non-small cell lung cancer .
Cat. No.: HY-175280
CAS No.: 3095033-62-5
Research Areas:
Lck degrader-1 is a molecular glue degrader that recruits cereblon to target LCK and CK1α. Lck degrader-1 promotes the formation of the LCK/CRBN-DDB1 ternary complex with an EC50 of 77.1 nM, and induces the degradation of LCK and CK1α. LCK degradation induced by Lck degrader-1 depends on the G415-containing helical G-loop degron, and maintains LCK-degrading activity in cells with the LCK T316I gatekeeper mutation. Lck degrader-1 can be used for research related to T-cell acute lymphoblastic leukemia (T-ALL) and LCK inhibitor resistance .
Cat. No.: HY-176702
CAS No.: 3078322-88-7
Target:
Research Areas:
PRMT5-MTA-IN-5 (Compound 7) is an orally active, irreversible PRMT5-MTA complex (PRMT5•MTA) inhibitor (IC50=1.15 nM). PRMT5-MTA-IN-5 blocks arginine methylation and inhibits ribosomal RNA processing and cell cycle-related protein expression. PRMT5-MTA-IN-5 potently inhibits proliferation in MTAP-deficient tumor cells. PRMT5-MTA-IN-5 is promising for research of MTAP-deficient solid tumors, such as liver, breast, and pancreatic cancers .
Cat. No.: HY-178042
CAS No.: 2756257-56-2
SS-3091 is a pan-KRas inhibitor active across KRas G12D, KRas G12C, KRas G12V, KRas G12S mutants, with minimal effects on non-KRas-driven cancer cells. SS-3091 binds to the KRas·ARaf interaction interface, destabilizes the complex, and attenuates KRas activity. SS-3091 suppresses phosphorylation of S6K, Akt, and ERK. SS-3091 reduces proliferation and decreases colony formation of cancer cells bearing KRas G12 mutations. SS-3091 can be used for the research of KRas-driven cancers .
Cat. No.: HY-180787
G6374 is a IRE1 PRORAC degrader with DC50 values of 0.04 μM (AMO1) and 0.13 μM (KMS27), an EC50 value of 0.11 μM, and KD values of 0.56 nM and 90.2 nM for IRE1 and VHL, respectively. G6374 binds to the ATP pocket of the IRE1 kinase domain and VHL to form a ternary complex that recruits CRL2 VHL, inducing K48-linked polyubiquitination of IRE1 at lysine residues K704 and K717, which in turn drives proteasomal degradation of monomeric and dimeric IRE1. G6374 can be used for the research of multiple myeloma .
Cat. No.: HY-180809
CAS No.: 3049753-10-5
YCH3292, a derivative of YCH189 (HY-155993) is a potent, selective and orally active PARP1/2 inhibitor with IC50 both <0.001 nM. YCH3292 can increase the stability of PARP-DNA complexes. YCH3292 exhibits robust antiproliferative activity. YCH3292 can induce double-strand breaks in DNA, increase the protein levels of γH2AX, P-RPA32, and P-Chk1 and induce tumor cells S or G2/M phase arrest and apoptosis. YCH3292 can inhibit tumor growth in MC38 xenograft model .
Cat. No.: HY-183080
CAS No.: 2872654-37-8
Research Areas:
VNRX-14079 is an antibacterial agent and PBP2 inhibitor, with an IC50 value of 1.7 μM against wild-type Neisseria gonorrhoeae PBP2. VNRX-14079 forms a covalent bond with Ser310 of PBP2, interacts with multiple residues of PBP2 to stabilize the complex, and induces an inward conformational change of the β3-β4 loop in chimeric PBP2. VNRX-14079 exhibits antibacterial activity against Ceftriaxone (HY-B0712)-resistant Neisseria gonorrhoeae strains. VNRX-14079 can be used in the research of gonorrhea .
Cat. No.: HY-183575
Target:
Research Areas:
JQ1-JX5 is a DCAF16-based BRD4 PROTAC degrader. JQ1-JX5 covalently modifies Cys58 of DCAF16, promotes ternary complex formation with BRD4, enables BRD4 ubiquitination and proteasomal degradation. JQ1-JX5 induces time-dependent degradation of BRD4 long and short isoforms in AGS cells with DC50 of 43.97 and 16.77 nM. JQ1-JX5 can be used for the research of cancer, such as acute myeloid leukemia .
Cat. No.: HY-183644
Target:
Research Areas:
LNO 9 is an orally active LOXL2 inhibitor and NO donor, with an IC50 of 0.17 μM against human LOXL2. LNO 9 competitively binds to the LTQ cofactor of LOXL2 to form an irreversible complex, thereby inhibiting collagen oxidation and abnormal cross-linking. LNO 9 releases nitric oxide (NO) to increase cGMP levels in pulmonary artery smooth muscle cells. LNO 9 inhibits hypoxia-induced collagen modification and possesses vasodilatory activity. LNO 9 ameliorates right ventricular hypertrophy and pulmonary artery medial thickness in rat models induced by hypoxia and Monocrotaline (HY-N0750), and can be used for research on pulmonary hypertension .
Cat. No.: HY-183984
Target:
Research Areas:
G-quadruplex ligand 6 is a G-quadruplex ligand targeting the c-MYC promoter with anti-tumor activity. G-quadruplex ligand 6 forms a non-covalent complex with Pu22, a G-quadruplex model of the c-MYC promoter, with a microscopic dissociation constant Kd of 0.202 μM. G-quadruplex ligand 6 selectively inhibits tumor cell proliferation, blocks the binding of transcription factors by stabilizing the G-quadruplex in the c-MYC promoter, and thereby regulates the expression of proto-oncogenes. G-quadruplex ligand 6 can be used in the research of pancreatic cancer, non-small cell lung cancer, colorectal cancer, and triple-negative breast cancer .
Cat. No.: HY-184106
CAS No.: 1268273-85-3
HSP70-IN-9 is an Hsp70 inhibitor that induces caspase-3,7 activation with an IC50 of 25.2 μM. HSP70-IN-9 reversibly binds to the allosteric pocket of the N-terminal domain, disrupts the Hsp70-HOP-Hsp90 mega-complex, and inhibits client protein refolding, thereby inducing apoptosis and degradation of Hsp90-Hsp70 tumor client proteins, ultimately inhibiting cancer cell growth. HSP70-IN-9 can be used for research on breast cancer, pancreatic cancer, and acute myeloid leukemia .
Cat. No.: HY-184657
Target:
Research Areas:
CDK2 degrader 10 is an orally active, cereblon-based molecular glue degrader targeting CDK2, with a DC50 of 120 nM. CDK2 degrader 10 forms a ternary complex with cereblon and CDK2 via a non-canonical recruitment mode, thereby driving CDK2 degradation through the ubiquitin-proteasome system. CDK2 degrader 10 inhibits retinoblastoma protein phosphorylation, induces G1/S cell cycle arrest, and suppresses CDK2-dependent cell proliferation. CDK2 degrader 10 can be used in studies related to CDK2-dependent cancers .
Cat. No.: HY-187533
EGFR AUTOTAC-1 is a p62/SQSTM1-directed EGFR AUTOTAC degrader. EGFR AUTOTAC-1 recruits p62 to form a ternary complex, activates the ubiquitin-proteasome system-independent Atg5-dependent autophagy-lysosome pathway, mediates autophagic degradation of EGFR and inhibits the AKT/ERK signaling pathway, thereby promoting apoptosis and activating autophagy. EGFR AUTOTAC-1 can be used for the research of non-small cell lung cancer.(Pink: EGFR ligand (HY-79511); Blue: p62 ligand (HY-187557); Black: Linker)
Cat. No.: HY-187716
Target:
Research Areas:
PROTAC 3CPro degrader-1 is a picornavirus 3C protease (3CPro) PROTAC degrader with an DC50 value of 0.16 μM. PROTAC 3CPro degrader-1 directly inhibits the catalytic function of 3CPro, induces degradation via the ubiquitin-proteasome pathway, and binds to CRBN to form a ternary complex. PROTAC 3CPro degrader-1 inhibits viral replication, degrades drug-resistant EV71 3CPro mutants, and exhibits broad-spectrum activity against multiple picornavirus 3CPro variants. PROTAC 3CPro degrader-1 can be used in studies related to picornavirus infections .
Cat. No.: HY-DY1111
CAS No.: 1539318-40-5
Target:
Research Areas:
DFHBI-2T solution is a membrane-permeable, RNA aptamer-activated fluorescent probe (Ex/Em=500 nm/523 nm), with a Kd value of 1300 nM for the RNA aptamer Spinach2. DFHBI-2T solution binds to Spinach2, converting the fluorophore to a fluorescent state, stabilizing its planar structure to facilitate the radiative fluorescence decay pathway, and forming a complex with red-shifted excitation and emission peaks. DFHBI-2T solution can be used for RNA imaging in live cells. It is also applicable to research related to fragile X-associated tremor/ataxia syndrome .
Solvent and concentration: DMSO: 5 mM
Solvent and concentration: DMSO: 5 mM
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
